For individuals with life-threatening food allergies, everyday activities like dining out and traveling can be tremendously stressful, as even the smallest traces of the allergen
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
Advocates of fasting point to the potential health and longevity benefits, often citing results from animal studies. However, the impact of prolonged calorie restriction on
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31, 2025,
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the Clinical
Marc, a 63-year-old from Bordeaux, France, has lived with Parkinson’s disease for more than two decades. The disease had increasingly hindered his mobility, causing balance
Psychiatric treatment is undergoing a profound shift as once-stigmatized psychedelic drugs gain mainstream acceptance. For instance, the Food and Drug Administration (FDA) approved a variant
Adding to research suggesting that vaccines for certain viral diseases may make someone less vulnerable to dementia later in life, a recent study demonstrates an association between
Following 30 years of research and development, the first malaria vaccine was recommended by the World Health Organization (WHO) for widespread use in children living
Recent advancements have led to the development of new cancer therapies that target mutations in KRAS proteins, which were once considered untreatable. In 2021, the
A recent Phase III clinical trial found that lecanemab reduces cognitive decline in patients with early Alzheimer’s disease (AD). The findings indicate that participants who
In August 2022, the Food and Drug Administration (FDA) approved Cimerli™ (ranibizumab-eqrn) as a biosimilar for Lucentis® (ranibizumab). In a time when high prescription costs
For individuals with life-threatening food allergies, everyday activities like dining out and traveling can be tremendously stressful, as even the smallest traces of the allergen
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
Advocates of fasting point to the potential health and longevity benefits, often citing results from animal studies. However, the impact of prolonged calorie restriction on
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31, 2025,
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the Clinical
Marc, a 63-year-old from Bordeaux, France, has lived with Parkinson’s disease for more than two decades. The disease had increasingly hindered his mobility, causing balance
Psychiatric treatment is undergoing a profound shift as once-stigmatized psychedelic drugs gain mainstream acceptance. For instance, the Food and Drug Administration (FDA) approved a variant
Adding to research suggesting that vaccines for certain viral diseases may make someone less vulnerable to dementia later in life, a recent study demonstrates an association between
Following 30 years of research and development, the first malaria vaccine was recommended by the World Health Organization (WHO) for widespread use in children living
Recent advancements have led to the development of new cancer therapies that target mutations in KRAS proteins, which were once considered untreatable. In 2021, the
A recent Phase III clinical trial found that lecanemab reduces cognitive decline in patients with early Alzheimer’s disease (AD). The findings indicate that participants who
In August 2022, the Food and Drug Administration (FDA) approved Cimerli™ (ranibizumab-eqrn) as a biosimilar for Lucentis® (ranibizumab). In a time when high prescription costs
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
